Nuance Pharma Announces Dosing of First Patient in ENHANCE – China Phase 3 Trial for COPD
April 11, 2023Business Services
LONDON and RALEIGH, N.C., April 11, 2023 – Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or the “Company”), a clinical-stage …
Pharming announces the first commercial shipments of Joenja® (leniolisib) to patients in the U.S.
April 11, 2023Business Services
Leiden, The Netherlands, April 11, 2023: Pharming Group N.V. (“Pharming”) (Euronext Amsterdam: PHARM / Nasdaq: PHAR) announces the first commercial …
Avacta Opens First Two US Clinical Investigator Sites for AVA6000 Phase 1 Clinical Study
April 6, 2023Business Services
Avacta Group plc (AIM: AVCT), a life sciences company developing innovative, targeted oncology drugs and powerful diagnostics, announces the opening …
AstraZeneca’s Lynparza approved by NHS England
April 6, 2023Medical Communications
NHS England has approved the use of AstraZeneca’s Lynparza (olaparib) for the treatment of patients with breast cancer and prostate …
Synapse receives FDA approval for its NeuRx DPS to treat patients with stable SCI
April 6, 2023Research and Development
Synapse Biomedical has announced that it has gained premarket approval (PMA) from the FDA for its NeuRxDiaphragm Pacing System (NeuRx …
Innova Care Concepts expand their support to the medical negligence sector with the acquisition of Nurture Group Ltd.
April 5, 2023Business Services
Press Release, Wednesday 5th April 2023, London… As part of a long-term strategy to increase its home adaptation services across …
Ipsen’s response to NICE’s decision on Cabometyx® (cabozantinib) for previously treated differentiated thyroid cancer unsuitable for or refractory to radioactive iodine
April 5, 2023Business Services
SLOUGH, UK, 5th April 2023 – Ipsen is disappointed that the National Institute for Health and Care Excellence (NICE) …
Syncona Appoints Roel Bulthuis as Managing Partner
April 5, 2023Business Services
05 April 2023 Syncona Ltd, a leading healthcare company focused on creating, building and scaling global leaders in life …
First Patient Dosed in Fifth Cohort of AVA6000 Phase Ia Dose Escalation Study
April 5, 2023Business Services
Avacta Group plc (AIM: AVCT), a life sciences company developing innovative, targeted oncology drugs and powerful diagnostics, announces that the …
BenevolentAI announces top-line Phase IIa results for its topical pan-Trk inhibitor BEN-2293 (1%) in mild-to-moderate atopic dermatitis
April 5, 2023Business Services
London, UK, 5 April 2023: BenevolentAI (“BenevolentAI” or the “Company”) (Euronext Amsterdam: BAI) announces top-line results from its Phase IIa, …
AstraZeneca reports positive results of drug combination in late-stage ovarian cancer trial
April 5, 2023Medical Communications
AstraZeneca has announced positive high-level results from an interim analysis of the DUO-O phase 3 trial assessing a combination of …
FDA requires prepaid mail-back envelopes for opioid analgesics
April 5, 2023Medical Communications
The FDA has announced that it will require opioid analgesic manufacturers to provide prepaid mail-back envelopes in outpatient pharmacies and …
Phlo acquires Truepill UK in landmark digital pharmacy consolidation
April 4, 2023Business Services
Glasgow, UK. Phlo Technologies UK digital pharmacy leaders, have today announced their acquisition of the UK arm of US-based healthcare …
Mosaic Therapeutics closes $28m series A funding and appoints Brian Gladsden as CEO
April 4, 2023Business Services
Cambridge, UK, 04 April 2023 – Mosaic Therapeutics, Ltd, (‘Mosaic’, or ‘the Company’) an oncology therapeutics company dedicated to resolving …
Recipharm bolsters senior leadership team with appointment of Joaquim Mascaro as Chief Financial Officer
April 4, 2023Business Services
Global contract development and manufacturing organisation (CDMO) Recipharm, has announced the appointment of Joaquim Mascaro as Chief Financial Officer.
Optibrium Appoints Computational Modelling Expert, Dr Hamed Tabatabaei Ghomi as Head of Research
April 4, 2023Business Services
Appointment will lead research strategy to apply the latest scientific innovations to Optibrium’s computational and AI drug discovery technologies Hamed …
Landmark data published on successful NTCD-M3 gut colonisation after fidaxomicin administration
April 4, 2023Business Services
Brighton, United Kingdom – 4 April 2023 – Destiny Pharma (AIM: DEST), a clinical stage innovative biotechnology company focused on …
PHARMANOVIA RECEIVES SBTi APPROVAL FOR NET ZERO EMISSION TARGETS
April 4, 2023Business Services
Basildon, UK, 3 April 2023 Pharmanovia, a global pharmaceutical company that revitalises, extends and expands the lifecycle of already established …
Ingenza appoints Steve Jones as its new Chief Financial Officer
April 4, 2023Business Services Ingenza
Ingenza appoints Steve Jones as its new Chief Financial Officer
Orbit Discovery and Evergreen Discovery collaborate to discover peptides for targeting radiopharmaceuticals
April 4, 2023Business Services
New Jersey, USA, and Oxford, UK, 3rd April 2023: Evergreen Discovery (Evergreen), a leading radiopharmaceutical drug development company with a …
Latest content
FibroFind appoints Lee Borthwick as CEO
